Sun Miaomiao, Wang Fuquan, Li Haopeng, Li Mengyu, Wang Yu, Wang Chenchen, Zhang Yan, Zhang Dingyu, Li Jianhua, Yao Shanglong
Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Institute of Anesthesia and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
J Inflamm Res. 2024 Feb 27;17:1349-1364. doi: 10.2147/JIR.S442729. eCollection 2024.
Sepsis-associated acute kidney injury (SA-AKI) is a common complication in patients with sepsis, triggering high morbidity and mortality. Maresin-1 (MaR1) is a pro-resolution lipid mediator that promotes the resolution of acute inflammation and protects organs from inflammation.
In this study, we established an SA-AKI model using cecal ligation and puncture (CLP) and investigated the effect and mechanism of MaR1. The blood and kidneys were harvested 24 hours after surgery. The blood biochemical/routine indicators, renal function, SA-AKI-related pathophysiological processes, and AMPK/SIRT3 signaling in septic mice were observed by histological staining, immunohistochemical staining, Western blot, qPCR, ELISA and TUNEL Assay.
MaR1 treatment alleviated kidney injury in septic mice, reflected in improved pathological changes in renal structure and renal function. MaR1 treatment decreased the levels of serum creatinine (sCr) and blood urea nitrogen (BUN) and the expressions of KIM-1, NGAL and TIMP-2, which were related to kidney injury, while inhibited the expressions of inflammatory factors TNF-α, IL-1β and IL-6. The expression of endoplasmic reticulum stress-related indicators p-PERK/PERK, GRP78, p-EIF2α/EIF2α, ATF4, CHOP, and pyroptosis-related indicators Caspase-1, NLRP3, GSDMD, IL-18, and IL-1β also decreased after MaR1 treatment. The mechanism may be related to the activation of the AMPK/SIRT3 signaling pathway, and an AMPK inhibitor (compound C) partially reverses MaR1's protective effects in septic mice.
Taken together, these findings suggest that MaR1 may partially ameliorate SA-AKI by activating the AMPK/SIRT3 signaling pathway, providing a potential new perspective for research on SA-AKI.
脓毒症相关急性肾损伤(SA-AKI)是脓毒症患者常见的并发症,会引发高发病率和死亡率。maresin-1(MaR1)是一种促消退脂质介质,可促进急性炎症的消退并保护器官免受炎症侵害。
在本研究中,我们采用盲肠结扎和穿刺(CLP)建立了SA-AKI模型,并研究了MaR1的作用及其机制。术后24小时采集血液和肾脏样本。通过组织学染色、免疫组化染色、蛋白质免疫印迹法、实时定量聚合酶链反应、酶联免疫吸附测定和末端脱氧核苷酸转移酶介导的缺口末端标记法观察脓毒症小鼠的血液生化/常规指标、肾功能、SA-AKI相关病理生理过程以及AMPK/SIRT3信号通路。
MaR1治疗减轻了脓毒症小鼠的肾损伤,表现为肾脏结构和肾功能的病理变化得到改善。MaR1治疗降低了血清肌酐(sCr)和血尿素氮(BUN)水平以及与肾损伤相关的KIM-1、NGAL和TIMP-2的表达,同时抑制了炎症因子TNF-α、IL-1β和IL-6的表达。MaR1治疗后,内质网应激相关指标p-PERK/PERK、GRP78、p-EIF2α/EIF2α、ATF4、CHOP以及焦亡相关指标Caspase-1、NLRP3、GSDMD、IL-18和IL-1β的表达也降低。其机制可能与AMPK/SIRT3信号通路的激活有关,AMPK抑制剂(化合物C)部分逆转了MaR1对脓毒症小鼠的保护作用。
综上所述,这些研究结果表明MaR1可能通过激活AMPK/SIRT3信号通路部分改善SA-AKI,为SA-AKI的研究提供了一个潜在的新视角。